Halothane (Fluothane) Veterinary Grade API is supplied as a clear, mobile, nonflammable liquid stabilized with thymol at 0.01% w/w; the physicochemical profile imposes an absolute boundary on formulation geography. The liquid exhibits a boiling point of 50.2 °C, vapor pressure of 32.5 kPa at 20 °C, and density near 1.87 g/mL, placing it outside the unit-operation envelope of wet granulation, direct compression, capsule filling, powder blending, premix extrusion, or lyophilization. The current USP Halothane monograph requires the presence of thymol as a stabilizer in amber glass containers, and the substance is intended only for delivery through a temperature-compensated, halothane-specific vaporizer. Published data for stable encapsulation, tablet compression, or oral premix formulation of a liquid active with vapor pressure above 20 kPa is limited. The following downstream applications describe real veterinary sectors where halothane retains an active, albeit niche, use profile.

Equine Closed-Circuit Anesthesia Requires Vaporizer Output Verification Below 0.5% Dial Resolution

In large-bore equine circle systems, halothane is delivered through an out-of-circuit, temperature-compensated vaporizer keyed only for halothane; cross-filling with isoflurane or sevoflurane is physically prevented on current ISO 8835-3 compatible filler systems. The reported approximate minimum alveolar concentration (MAC) for halothane in the horse is 0.88% end-tidal, and a surgical plane is maintained at 1.2–1.5 times MAC, equating to an end-tidal concentration of 1.1–1.4% in oxygen. Induction typically requires a vaporizer dial setting of 3.5–4.0% for 3–5 minutes after intravenous induction with a ketamine–diazepam combination and orotracheal intubation with a cuffed silicone endotracheal tube of 22–26 mm internal diameter. Once the animal is positioned in dorsal recumbency, fresh gas flow is reduced stepwise from 8–10 L/min to 3–4 L/min in a circle rebreathing system equipped with fresh soda lime and a 10 L reservoir bag. The process is managed with continuous electrocardiography, direct arterial pressure transducers, and capnography maintaining PaCO₂ between 35–45 mmHg; hypotension with mean arterial pressure below 60 mmHg is common at depths above 1.5 MAC and is treated with dobutamine infusion rates of 0.5–5 µg/kg/min, not with epinephrine, due to halothane-induced myocardial sensitization to catecholamines. The terminal finished state is a stable surgical plane for orthopedic, colic, or soft-tissue procedures lasting 60–240 minutes. For compliance, the halothane liquid must conform to the current USP Halothane monograph, and vaporizer output is verified against an infrared gas analyzer calibrated using a reference gas cell traceable to a national metrology institute; a dial offset of more than 0.5% absolute at the 2% setting requires recalibration or replacement of the vaporizer.

In companion animal surgical suites, the same halothane API is charged into small-animal precision vaporizers with a dial resolution of 0.2% and a low-flow oxygen meter graduated in 0.1 L/min increments. For canine ovariohysterectomy, orchiectomy, or mass removal, premedication with an opioid–tranquilizer combination is followed by propofol induction and intubation; halothane is then started at 3.0% on a non-rebreathing system for patients under 10 kg or a circle system for larger patients. The maintenance concentration is titrated to body weight, temperature, and surgical stimulation within 1.3–1.8% for dogs and 1.5–2.0% for cats, corresponding to reported approximate MAC values of 0.87% and 1.14% respectively. Fresh gas flow is initially set at 30–50 mL/kg/min but may be lowered only after 10–15 minutes of equilibration because halothane’s blood/gas partition coefficient of approximately 2.4 creates a slower wash-in than sevoflurane. On production lines for veterinary vaporizer filling, the receiving bottle is amber glass with a keyed collar and a moisture-resistant closure; residual water ingress is controlled by Karl Fischer titration under USP 921 to remain within the supplier certificate of analysis. The end product is a stable anesthetic plane for procedures typically lasting 20–90 minutes; recovery is extended in obese animals and in brachycephalic breeds due to delayed redistribution from adipose tissue, requiring extubation only after return of swallowing reflex and spontaneous ventilation with end-tidal halothane below 0.3%.

Why Does Thymol Accumulate in Low-Flow Rodent Exposure Systems?

In laboratory rodent anesthesia, halothane is delivered from a calibrated vaporizer into a transparent polycarbonate induction chamber at 2.5–3.0% v/v with oxygen flow 1–2 L/min for 90–120 seconds; rats then are transferred to a nose cone for maintenance at 1.2–1.5% end-tidal against a reported approximate rat MAC of 0.95%. The question of thymol accumulation arises because thymol at 0.01% w/w has a vapor pressure far lower than halothane; during low-flow operation and repeated refill cycles without draining the vaporizer sump, the less volatile thymol can remain in the wick and interior surfaces, raising the effective concentration in the vaporization chamber over weeks of continuous laboratory use. This creates a diagnostically relevant artifact: a progressive odor shift, a visible oily film on the sight glass, and a downward shift in output calibration as the wick becomes coated, requiring vaporizer tear-down and cleaning according to the ISO 8835-3 service interval. Exposure protocols for rodents are therefore written with a requirement to drain and discard the residual liquid every 30 operating days and to replace the vaporizer wick annually or after every 500 halothane refill cycles. Compliance in university vivaria is bound to institutional animal care and use committee protocols and the Guide for the Care and Use of Laboratory Animals; waste gas is scavenged through a charcoal canister certified by the manufacturer for halogenated anesthetic agents, with canister breakthrough monitored by weight gain within 10% of labeled capacity. The terminal finished state is surgical-grade anesthesia for catheter placement, blood collection, or terminal procedures under non-recovery protocols. Published data for open-chamber exposure in neonatal rodents is limited; chambers must not be used for very small neonatal animals under 10 g body weight due to rapid hypothermia and dose overshoot.

Avian, reptile, and small-mammal exotic practice uses halothane in induction chambers because the vapor is heavier than air and fills a closed chamber predictably at low flow. A typical bird induction chamber receives 3.0–4.5% halothane at 1–2 L/min oxygen for 2–4 minutes, with the chamber partially covered to reduce visual stimulation; reptiles require lower concentrations of 2.0–3.0% and longer induction times of 15–30 minutes at ambient species-specific temperature because their circulatory shunting slows pulmonary uptake. Maintenance is delivered through a small face mask or modified syringe case at 1.0–2.5%, with a heating pad set to 35–39 °C for birds and 25–30 °C for snakes to offset halothane-induced vasodilation and hypothermia. The end product is a sedated or anesthetized patient for blood collection, radiography, beak trim, or mass excision. The same thymol-stabilized liquid is used, but the vaporizer must be dedicated to halothane; dial settings below 1.0% are unreliable in some older units due to resolution limitations and must be verified with an infrared gas monitor.

Compounded Vaporizer Solutions and the Absence of Solid or Parenteral Dosage Forms

The API cannot be converted into tablets, capsules, powders, granules, premix, or injectable solutions under any recognized veterinary compounding standard. The boiling point of 50.2 °C and vapor pressure of 32.5 kPa at 20 °C mean that wet granulation, tray drying, and dry blending operations would lose the active ingredient at rates that exceed the process capability of unit-dose uniformity; published data for quantitative evaporative loss during tablet compression of halothane is limited. Capsule filling and powder premix blending with feed carriers would violate volatile organic packaging requirements and create worker exposure during sifting and sack-off. Injectable solution formulation is contraindicated because halothane is a highly lipid-soluble liquid with no aqueous solubility stabilizer in its USP monograph; intravenous or intramuscular injection would not produce controlled anesthesia but would risk severe tissue injury and cardiac irritability. The only compliant liquid formulation is the original amber-glass vaporizer solution containing thymol 0.01% w/w, protected from light and stored at 15–30 °C in a tightly closed, vapor-tight container. For environmental compliance, disposal or spill handling follows the applicable national waste regulations for halogenated volatile organic compounds; aqueous transfer to drainage is not permitted. The dosage forms listed in the product title are therefore not downstream manufacturing routes; they are incorrect formulation assumptions that must be rejected at the technical review stage.

When a 450 kg Patient Is Transitioned from Isoflurane to Halothane Under Field Conditions

In mobile equine practice, changing from isoflurane to halothane in a 450 kg horse requires a complete vaporizer swap because the two agents have different saturated vapor pressures and require different splitting ratios inside the vaporizer; an isoflurane-calibrated vaporizer used with halothane may under-deliver or over-deliver by more than 1.0% absolute at the same dial setting. The vaporizer is filled to no more than 80% of the sight-glass upper line, after confirming the liquid is clear with no sediment and has been stored in the original amber glass bottle between 15–30 °C. The field anesthesia circuit is checked for soda lime moisture content; fully desiccated absorbent is replaced because it can degrade halogenated anesthetics. Induction begins with 3.5% halothane in oxygen at 8 L/min, and the horse is intubated with a cuffed tube and placed in lateral recumbency; maintenance is titrated to 1.2–1.4% end-tidal with a portable infrared gas analyzer. The terminal finished state is surgical anesthesia for castration, laceration repair, or emergency colic referral. This conversion procedure is documented in facility standard operating procedures and is covered by veterinary prescription controls for volatile anesthetic agents.